

リウマチ・膠原病内科グループ 英語論文の業績 2019年

- 1) Maeda S, Osaga S, Maeda T, Takeda N, Tamechika SY, Naniwa T, Niimi A. Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research. PLoS One. 20;14(11):e0215192, 2019
- 2) Ohmura SI, Naniwa T, Tamechika SY, Miyamoto T, Shichi D, Kazawa N, Iwagaitsu S, Maeda S, Wada JI, Niimi A. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for *Pneumocystis jirovecii* pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study. J Infect Chemother. 25(4):253-261, 2019
- 3) Yamagata K, Usui J, Nagata M, Sugiyama H, Sada KE, Muso E, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, Kobayashi M, Saito T, Ito T, Hirawa N, Homma S, Dobashi H, Tsuboi N, Ishizu A, Arimura Y, Makino H, Matsuo S; Research Committee of Intractable Renal Disease and the Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health, Labour, and Welfare of Japan. Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study. Clin Exp Nephrol. 2019;23(3):387-394.
- 4) Nagasaka K, Harigai M, Hagino N, Hara A, Horita T, Hayashi T, Itabashi M, Ito S, Katsumata Y, Kawashima S, Naniwa T, Sada KE, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Homma S, Arimura Y. Systematic review and meta-analysis for 2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis. Mod Rheumatol. 29(1):119-129, 2019